Sign In
Buy VSTM
$5.37
-0.160 (-2.89%)
At Close: Jul 13, 2026
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
06:46am, Friday, 10'th Jul 2026
Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 02'nd Jul 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
08:32pm, Tuesday, 23'rd Jun 2026
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.
Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program
02:43pm, Wednesday, 17'th Jun 2026
Verastem, Inc. is maintained at a Buy rating, driven by upcoming clinical catalysts and positive early-stage data in KRAS G12D mutant solid tumors. VSTM expects key data readouts from the TARGET-D 101
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
12:45pm, Wednesday, 17'th Jun 2026
Verastem, Inc. (NASDAQ:VSTM) stock is trading higher on Wednesday as the company announced positive updated results from its RAMP 205 trial, which evaluates the efficacy of its drug combination in tre
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma.
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 201, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated advanced pancreatic cancer.
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem Oncology to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D program and updated Phase 1/2 TARGET-D 101 data.
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--FDA grants Fast Track designation to VS-7375, an oral investigational KRAS G12D inhibitor, for locally advanced or metastatic KRAS G12D-mutated NSCLC.
Verastem Oncology to Present at Jefferies Healthcare Conference
08:00am, Wednesday, 27'th May 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann
Verastem Oncology to Present at Jefferies Healthcare Conference
07:30am, Wednesday, 27'th May 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
07:30am, Tuesday, 26'th May 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appoi
Cancer Stocks That Are Advancing the Future of Oncology Care
01:01pm, Monday, 18'th May 2026
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Monday, 18'th May 2026
The heavy selling pressure might have exhausted for Verastem (VSTM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
